An AACR Special Conference in Cancer Research

Pancreatic Cancer
September 29-30, 2021 | Virtual Special Conference

Conference Cochairs:
Andrew M. Lowy, UC San Diego, La Jolla, CA
Marina Pasca di Magliano, University of Michigan Medical School, Ann Arbor, MI
Robert H. Vonderheide, Penn Medicine Abramson Cancer Center, Philadelphia, PA
Jen Jen Yeh, University of North Carolina, Chapel Hill, NC

All times listed are in Eastern Time, US

WEDNESDAY, SEPTEMBER 29
10:00 a.m.-10:45 a.m. Opening Session
10:00 a.m.-10:05 a.m. Welcome from Cochairs
Marina Pasca di Magliano, University of Michigan Medical School, Ann Arbor, MI

10:05 a.m.-10:10 a.m. Welcome from Lead Supporters
Linda Tantawi, Lustgarten Foundation, Woodbury, NY

10:10 a.m.-10:45 a.m. Rising Star Keynote
Molecular subtypes and vulnerabilities in pancreatic cancer
Andrew J. Aguirre, Dana-Farber Cancer Institute, Boston, MA

10:45 a.m.-11:00 a.m. BREAK

11:00 a.m.-12:45 p.m. Session 1-Immunotherapy Translation in Progress
Moderator: Robert H. Vonderheide, Penn Medicine Abramson Cancer Center, Philadelphia, PA

11:00 a.m.-11:25 a.m. Session Keynote: Dendritic cell corner stone of tumor immunity in PDAC
David G. DeNardo, Washington University School of Medicine, St. Louis, MO

11:25 a.m.-11:40 a.m. Ex vivo co-culture system with patient-derived organoids to assess CXCR4 inhibitor as an immune modulating agent for human pancreas adenocarcinoma
Emily Alouani*, Columbia University, New York, NY

11:40 a.m.-11:55 a.m. A phase II pilot trial of nivolumab (N) + albumin bound paclitaxel (AP) + paricalcitol (P) + cisplatin (C) + gemcitabine (G) (NAPPCG) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC)
Erkut H. Borazanci*, HonorHealth/TGen, Scottsdale, AZ

11:55 a.m.-12:10 p.m. High quality neoantigens are immunoedited in long-term pancreatic cancer survivors
Luis A. Rojas*, Memorial Sloan Kettering Cancer Center, New York, NY

*Short talk selected from proffered abstracts
AACR Special Conference: Pancreatic Cancer
September 29-30, 2021 | Virtual Special Conference
12:10 p.m.-12:25 p.m.  Inhibition of focal adhesion kinase (FAK) improves pancreatic ductal adenocarcinoma’s response to immunotherapy by targeting cancer stem cells (CSCs)  
Yezi Zhu*, Livestrong Cancer Institute, Austin, TX

12:25 p.m.-12:30 p.m.  Discussant: Reginald Hill, Ellison Institute for Transformative Medicine of USC, Los Angeles, CA

12:30 p.m.-12:45 p.m.  Discussion

12:45 p.m.-1:15 p.m.  BREAK

1:15 p.m.-2:00 p.m.  Career Breakout Rooms

  o Transitioning from Academics to Industry
    ▪  David J. Shields, Pfizer, New York, NY
    ▪  Christina Twyman-Saint Victor, Bristol-Myers Squibb, Piscataway, NJ
  o Collaborating with Industry
    ▪  Jane Grogan, Graphite Bio, South San Francisco, CA
    ▪  Channing Der, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC
  o Starting Your Lab
    ▪  Yuliya Pylayeva-Gupta, University of North Carolina at Chapel Hill
    ▪  Christopher J. Halbrook, University of California Irvine, Irvine, CA
  o Getting Tenure
    ▪  Zobeida Cruz-Monserrat, The Ohio State University Wexner Medical Center, Columbus, OH
    ▪  Rushika M. Perera, University of California San Francisco, San Francisco, CA
  o Balancing Clinical and Research Life
    ▪  Susan Tsai, Medical College of Wisconsin, Wauwatosa, WI
    ▪  Jen Jen Yeh, University of North Carolina, Chapel Hill, NC
  o Mentoring the Mentor
    ▪  Lisa M. Coussens, OHSU Knight Cancer Center, Portland, OR
    ▪  Howard C. Crawford, Henry Ford Pancreatic Cancer Center, Detroit, MI

2:00 p.m.-2:30 p.m.  BREAK

2:30 p.m.-4:00 p.m.  Session 2-Big Data

  Moderator: Jen Jen Yeh, University of North Carolina, Chapel Hill, NC

  2:30 p.m.-3:00 p.m.  Session Keynote
  Proteogenomic characterization of pancreatic ductal adenocarcinoma  
  Hui Zhang, Johns Hopkins University, Baltimore, MD

*Short talk selected from proffered abstracts
AACR Special Conference: Pancreatic Cancer
September 29-30, 2021 | Virtual Special Conference
An AACR Special Conference in Cancer Research

**Pancreatic Cancer**
September 29-30, 2021 | Virtual Special Conference

3:00 p.m.-3:15 p.m.  Chromatin dynamics *in vivo* define coordinate functions of inflammation and mutant Kras in pancreatic tumorigenesis
Rohit Chandwani*, Weill Cornell Medicine, New York, NY

3:15 p.m.-3:30 p.m.  Integrative genomic characterization of therapeutic targets for pancreatic cancer
Jimmy A. Guo*, Broad Institute of MIT and Harvard, Cambridge, MA

3:30 p.m.-3:45 p.m.  Lung-tropic, liver-averse, primary PDAC tumors are associated with greater peripheral T cell diversity and have a unique, subtype-independent, gene-expression signature that significantly correlates with longer survival
Jason M. Link*, Oregon Health & Science University, Portland, OR

3:45 p.m.-3:50 p.m.  Discussant 2: Eric A. Colisson, University of California San Francisco, San Francisco, CA

3:50 p.m.-4:00 p.m.  Discussion

**THURSDAY, SEPTEMBER 30**

10:00 a.m.-10:45 a.m.  Keynote Lecture
*Moderator: Jen Jen Yeh, University of North Carolina, Chapel Hill, NC*

Using an integrative molecular epidemiology approach to battle pancreatic cancer in the era of precision medicine: Hope is on the horizon
Jennifer B. Permuth, H. Lee Moffitt Cancer Center, Tampa, FL

10:45 a.m.-11:00 a.m.  BREAK

11:00 a.m.-12:45 p.m.  Session 3-Metabolism and Ras Signaling
*Moderator: Andrew M. Lowy, UC San Diego, La Jolla, CA*

11:00 a.m.-11:25 a.m.  Session Keynote:
**Metabolic stress in pancreatic cancer progression and therapy**
Cosimo Commissso, Sanford Burnham Prebys Medical Discovery Institute, San Diego, CA

11:25 a.m.-11:40 a.m.  Kdm6 demethylases are critical regulators of pancreatic cancer initiation, progression and subtype specification
Laura Leonhardt*, University of California San Francisco, San Francisco, CA

11:40 a.m.-11:55 a.m.  Targeting the sterol regulatory element-binding protein pathway in pancreatic ductal adenocarcinoma
Stephanie Myers*, Johns Hopkins University, Baltimore, MD

*Short talk selected from proffered abstracts*
AACR Special Conference: Pancreatic Cancer
September 29-30, 2021 | Virtual Special Conference  
Page 3 of 5
Collateral amplification of the KRAS linked gene PTHLH governs pancreatic cancer growth and metastasis and reveals a new therapeutic vulnerability
Jason R. Pitarresi*, University of Pennsylvania, Philadelphia, PA

Loss of compensatory feedback mechanism involving splicing factor SRSF1 accelerates Kras<sup>G12D</sup>-mediated pancreatic cancer initiation
Ledong Wan*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

Discussant- Donita Brady, Perelman School of Med. Univ. of Pennsylvania

12:45 p.m.-1:15 p.m.  BREAK

1:15 p.m.-3:05 p.m.  Session 4-Tumor Microenvironment
Moderator: Marina Pasca Di Magliano, University of Michigan Medical School, Ann Arbor, MI

Session Keynote
Rebalancing dysregulated tumor microenvironments in pancreatic cancer progression
Rosandra N. Kaplan, National Cancer Institute, Bethesda, MD

The splanchnic mesenchyme during fetal development is the major source of pancreatic cancer associated fibroblasts
Lu Han*, Medical University of South Carolina, Charleston, SC

Hedgehog represses angiogenesis in PDAC through a paracrine cascade mediated by Wif1
Marie C. Hasselluhn*, Columbia University, New York, NY

Cancer-associated fibroblasts sustain critical dependency of pancreatic cancer cells on exogenous lipids
Charline Ogier*, Fox Chase Cancer Center, Philadelphia, PA

Extrinsic KRAS signaling shapes the pancreatic microenvironment through fibroblast reprogramming
Ashley Velez-Delgado*, University of Michigan, Ann Arbor, MI

Discussant: Mara H. Sherman, OHSU Knight Cancer Center, Portland, OR
2:45 p.m.-3:05 p.m.  Discussion

3:05 p.m.-3:30 p.m.  BREAK

3:30 p.m.-4:30 p.m.  Debate: The KPC model has helped advance pancreatic cancer therapy: Agree or disagree?
Moderator: Anirban Maitra, UT MD Anderson Cancer Center, Houston, TX
  3:30 p.m.-3:50 p.m.  Kenneth P. Olive, Herbert Irving Comprehensive Cancer Center, New York, NY
  3:50 p.m.-4:10 p.m.  Phoebe Phillips, University of New South Wales, Sydney, Australia
  4:10 p.m.-4:30 p.m.  Discussion

4:30 p.m.-4:35 p.m.  Closing Statements
Andrew M. Lowy, UC San Diego, La Jolla, CA